◼ Archived
Business
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Amgen
6 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✓
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
◼ Archived
Business
🔮 fades ✓
Stock Market Today: Dow tumbles 1%, S&P 500 and Nasdaq drop as Brent crude edges toward $100 a barrel and pharma stocks stumble
U.S. stocks tumble as crude oil approaches $100 per barrel and inflation data approaches.
◼ Archived
Business
🔮 fades ✗
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
◼ Archived
Business
🔮 holds ✗
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.